Sotabase

Career

· Member, Operators Guild2025–
· Founder, Diamond Arc Legacy2024–
· Entrepreneur In Residence, Next Coast Legacy2024–
· Vice President Of Operations, TEAM Public Choices2022–2024
· Operating Executive, Alpine Investors2020–2024
· Director Of Operations And M A, TEAM Public Choices2020–2021
· Co-Founder, TourneyLand2019–2019
· Private Equity Associate, Beecken Petty O'Keefe & Company2016–2018
· Investment Banking Analyst, Houlihan Lokey2013–2016
· Investment Banking Summer Analyst, Brown Gibb

Publications (73)

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
Journal of Clinical Oncology · 2004
1,744
cited
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Journal of Clinical Oncology · 2004
505
cited
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Journal of Clinical Oncology · 2006
306
cited
Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994.
Jornal de Pediatria · 1997
246
cited
The presence and intensity of the cetuximab- induced acne-like rash predicts increased survival in studies across multiple malignances
2003
213
cited
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Journal of Clinical Oncology · 2005
207
cited
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
The Lancet Oncology · 2019
178
cited
Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Ophthalmology (Rochester, Minn.) · 1997
164
cited
Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma
Investigational new drugs · 2003
158
cited
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Journal of Clinical Oncology · 2005
154
cited
Adjuvant chemotherapy for the treatment of intracranial ependymoma of childhood
Cancer · 1997
130
cited
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.
Clinical Cancer Research · 2003
128
cited
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.
Journal of Clinical Oncology · 2004
112
cited
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors.
Medical and Pediatric Oncology · 1997
105
cited
Neuropsychological Profile of Children With Neurofibromatosis, Brain Tamor, or Both
Journal of Child Neurology · 1994
85
cited
Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.
Journal of Neurosurgery: Pediatrics · 2013
84
cited
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Seminars in Oncology · 2002
82
cited
Treatment of diencephalic syndrome with chemotherapy
Cancer · 1998
80
cited
Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant β‐interferon and hyperfractionated radiation therapy: A Childrens Cancer Group phase I/II study
Cancer · 1996
77
cited
Central nervous system medulloepithelioma: a series of eight cases including two arising in the pons.
Journal of Neurosurgery · 1996
70
cited
Sotabase